Press Releases :: VolitionRx Ltd (VNRX)

Feb 5, 2025 9:15 am EST

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Jan 30, 2025 8:30 am EST

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Jan 8, 2025 8:30 am EST

Volition Issues Business Review 2024

Dec 12, 2024 8:00 am EST

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Dec 10, 2024 8:00 am EST

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Dec 6, 2024 9:00 am EST

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Nov 14, 2024 4:10 pm EST

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Nov 8, 2024 8:00 am EST

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Nov 6, 2024 4:10 pm EST

Volition Appoints Timothy I. Still as Chairman

Oct 31, 2024 8:00 am EDT

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

rss_feed News RSS